Weekly Dose of Optimism #219 · Not Boring by Packy McCormick
Health & Medicine · Nov 13, 2026
Argenx’s acquisition of Unnatural Products for up to $1.145 billion underscores the strategic value of macrocyclic peptide platforms that could deliver antibody-like precision in orally available, cell-permeable drugs. The deal includes $550 million upfront and up to $595 million in milestones, targets FcRn alongside Argenx’s Vyvgart franchise, and reflects the commercial potential of extending successful biologics into pill-based therapies.
Weekly Dose of Optimism #219 · Not Boring by Packy McCormick
Science, Technology & Innovation · Nov 13, 2026
SpaceX contracted SINGULUS to deliver a €60 million-plus heterojunction solar-cell production line to its Texas satellite factory by the first half of 2027, while signaling eventual capacity above 100 GW annually—far beyond the estimated needs of its proposed orbital data centers and current satellite fleet. The scale appears to reflect ambitious manufacturing intent rather than proven demand, but could still expand terrestrial clean-energy supply if developed.
Weekly Dose of Optimism #219 · Not Boring by Packy McCormick
Health & Medicine · Nov 13, 2026
A study found that LSD reversed molecular markers of brain aging in rodents and repaired amyloid-β-damaged neurons in vitro more strongly than exercise or enriched environments, but the findings are preclinical and do not demonstrate that LSD treats Alzheimer’s disease in humans.
Weekly Dose of Optimism #219 · Not Boring by Packy McCormick
Science, Technology & Innovation · Nov 13, 2026
Path Robotics’ $300 million Series E and $600 million HII contract highlight rising demand for adaptive welding robots that can inspect variable workpieces, generate custom weld plans, and adjust in real time—addressing skilled-labor shortages in defense, shipbuilding, construction, and other nonstandard industrial settings.
Weekly Dose of Optimism #219 · Not Boring by Packy McCormick
Science, Technology & Innovation · Nov 13, 2026
AlphaGenome 2 improves DNA-variant interpretation by predicting regulatory effects in specific tissues, cell types, and cell states, identifying 30% of causal variants in an immune-cell benchmark versus 16% for its predecessor. While it does not solve variant causality, its condition-specific predictions could narrow experimental searches and accelerate drug-target discovery.